Skip to main content
Addgene

pTRIPZ shNS
(Plasmid #127696)

Ordering

This material is available to academics and nonprofits only.
Item Catalog # Description Quantity Price (USD)
Plasmid 127696 Standard format: Plasmid sent in bacteria as agar stab 1 $85

Backbone

  • Vector backbone
    pTRIPZ RFP+
  • Backbone size w/o insert (bp) 13320
  • Total vector size (bp) 13412
  • Modifications to backbone
    insertion of non silencing shRNA hairpin sequence between XhoI and Eco RI restriction sites
  • Vector type
    Mammalian Expression, Lentiviral
  • Selectable markers
    Puromycin

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
    37°C
  • Growth Strain(s)
    NEB Stable
  • Copy number
    Unknown

Gene/Insert

  • Gene/Insert name
    shNS
  • Alt name
    non silencing shRNA
  • gRNA/shRNA sequence
    AATTCTCCGAACGTGTCACGT
  • Species
    H. sapiens (human), M. musculus (mouse)

Cloning Information

  • Cloning method Restriction Enzyme
  • 5′ cloning site XhoI (not destroyed)
  • 3′ cloning site EcoRI (not destroyed)
  • 5′ sequencing primer cagaaggctcgagaaggtatattgctgttgctgttgacagtgagcg
  • 3′ sequencing primer ctaaagtagccccttgaattccgaggcagtaggca
  • (Common Sequencing Primers)

Resource Information

Terms and Licenses

Trademarks:
  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pTRIPZ shNS was a gift from Sandra Demaria (Addgene plasmid # 127696 ; http://n2t.net/addgene:127696 ; RRID:Addgene_127696)
  • For your References section:

    DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, Coleman CN, Formenti SC, Demaria S. Nat Commun. 2017 Jun 9;8:15618. doi: 10.1038/ncomms15618. 10.1038/ncomms15618 PubMed 28598415